FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1830-1831 June 6, 2002 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Coiffier, B. PubMed Citation

To the Editor: The study by Coiffier et al. (Jan. 24 issue)¹ raises several issues. First, the Southwest Oncology Group had clearly established the superiority of three courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) followed by radiation in patients with stage I or II diffuse large-B-cell lymphoma by the time Coiffier et al. began their study.² Nevertheless, patients with stage II disease were given eight cycles of CHOP, which thus raises the ethical question of whether the therapy these patients received was more toxic than necessary.

Second, the central review of the diagnosis revealed that 49 patients with presumed . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Mohammad, R. M., Wang, S., Aboukameel, A., Chen, B., Wu, X., Chen, J., Al-Katib, A. (2005). Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL [(-)-gossypol] against diffuse large cell lymphoma. Molecular Cancer Therapeutics 4: 13-21 [Abstract] [Full Text]